IDEXX LABORATORIES INC /DE
Form 3
October 05, 2006

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0104
Expires:	January 31, 2005
Estimated average burden hours per response...	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Â Williams Michael J
(Last) (First) (Middle)

C/O IDEXX LABORATORIES, INC.,Â ONE IDEXX DRIVE
(Street)

WESTBROOK,Â MEÂ 04092
(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/27/2006

3. Issuer Name **and** Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [IDXX]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Corporate Vice President

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,238 (1)	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Title			

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Incentive Stock Option (right to buy)	Â (2)	01/06/2013	Common Stock	10,000	$ 32.78	D	Â
Incentive Stock Option (right to buy)	Â (3)	02/04/2014	Common Stock	4,064	$ 50.9	D	Â
Incentive Stock Option (right to buy)	Â (4)	02/02/2015	Common Stock	1,897	$ 57.31	D	Â
Incentive Stock Option (right to buy)	Â (5)	02/13/2013	Common Stock	839	$ 76.67	D	Â
Non-Qualified Stock Option (right to buy)	Â (3)	02/04/2014	Common Stock	2,736	$ 50.9	D	Â
Non-Qualified Stock Option (right to buy)	Â (4)	02/02/2015	Common Stock	4,903	$ 57.31	D	Â
Non-Qualified Stock Option (right to buy)	Â (5)	02/13/2013	Common Stock	1,922	$ 76.67	D	Â
Restricted Stock Unit	Â (6)	Â (6)	Common Stock	688	$ (6)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Williams Michael J C/O IDEXX LABORATORIES, INC. ONE IDEXX DRIVE WESTBROOK,Â MEÂ 04092	Â	Â	Â Corporate Vice President	Â

Signatures

Conan R. Deady, Attorney-in-Fact for Michael J. Williams	10/05/2006
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes 1,734 shares which represent deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Executive Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units acquired is determined by dividing the amount of cash compensation deferred pursuant to the Plan by the closing price of the IDEXX Laboratories, Inc. Common Stock on the date of the deferral. Deferred stock units are issuable only as common stock on a one-for-one basis one year following the Executive's resignation from IDEXX.

(2) Grant of option to buy shares of Common Stock exercisable in five equal annual increments, beginning on the first anniversary date (1/06/2004) of the date of grant.

(3)

Grant of option to buy shares of Common Stock exercisable in five equal annual increments, beginning on the first anniversary date (2/05/2005) of the date of grant.

(4) Grant of option to buy shares of Common Stock exercisable in five equal annual increments, beginning on the first anniversary date (2/03/2006) of the date of grant.

(5) Grant of option to buy shares of Common Stock exercisable in five equal annual increments, beginning on 02/14/2007.

(6) Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. Common Stock. The restricted stock units vest in five equal annual installments begining on February 14, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.